ACL
NKTR icon

APEIRON Capital Ltd’s Nektar Therapeutics NKTR Stock Holding History

APEIRON Capital Ltd’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.43M Buy
+106,431
New +$7.79M 4.77% 8

Other funds holding NKTR

EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

APEIRON Capital Ltd's NKTR Position: Q2 2026 in Review

APEIRON Capital Ltd opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 106,431 shares worth $7.43M. The stake represents 4.77% of the portfolio and ranks #8 among its holdings.

53 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • APEIRON Capital Ltd held 106,431 shares of Nektar Therapeutics worth $7.43M as of Q2 2026.
  • Nektar Therapeutics was a new APEIRON Capital Ltd position in Q2 2026.
  • Nektar Therapeutics made up 4.77% of APEIRON Capital Ltd's portfolio in Q2 2026, its #8 holding.
  • 53 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on APEIRON Capital Ltd's 13F filing for Q2 2026, filed 6 Aug 2026.